RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)
Recruiting · NCT03053141
Conditions: Cardiac Arrythmias
At a glance
- Research payments reported, 2025
- $2,908
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- Rhythmia Mapping System (device)
- Dates
- Started 2016-05; completion 2027-12
- Results posted
- Not yet
The objective of the RHAPSODY study is to evaluate the performance of new software features in subjects undergoing standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this study will be used to guide development and refinement of new software features that may be implemented in future commercial software releases.
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $2,908 in research payments for this study in 2025 (1 payments).
Products named: Rhythmia Mapping System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Manchester Health Services LLC $2,908
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.